Please assess the completion status of the following clinical trial:

Trial Title: PRISMA-PET - Primary Staging of Prostate Cancer With PSMA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has given informed consent to participate~* Can read and understand provided patient information material in Danish~* Biopsy verified PCa~* Any, some, or all of the following features:~  * Prostatic Specific Antigen (PSA) ≥ 20 ng/ml OR~ * Gleason Score ≥ 4+3 OR~ * Tumor stage clinically judged T2c cancer (cT2c) or above as determined by digital rectal exploration and/or transrectal ultrasonography~ * Suspicion of metastases clinically based on other findings~* Prostatic Specific Antigen (PSA) ≤ 200 ng/ml~* Staging by imaging warranted~Exclusion Criteria:~* Consent not given~* Inability to read and/or understand provided patient information in Danish~* Previously given consent but withdrawn for any reason~* Staging by imaging not warranted as judged clinically~* Allergy towards contents in the tracer solution

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A) Conventional Imaging (Type: NO_INTERVENTION): Conventional Imaging with NaF (sodium fluoride)-PET/CT used for staging
- B) Interventional Imaging (Type: EXPERIMENTAL): Staging with the interventional18F-PSMA-1007 PET/CT.

Based on this trial design, predict the completion outcome and termination type (if applicable).